

## Tick-Borne Disease Panel (TDP)

The **TDP** is a combination of serological and molecular assays to aid in the diagnosis of acute or chronic infection by the most common tick-borne agents in this area. This includes testing for Lyme Disease (*B. burgdorferi*); Rickettsial diseases, both Spotted-Fever Group (which includes Rocky Mountain Spotted Fever) and Typhus Group; *Pan-Ehrlichia* [*E. chaffeensis*, *E. muris eauclairensis*, and *E. ewingii* (Human Monocytic Ehrlichiosis)]; and *Anaplasma phagocytophilum* (Human Granulocytic Anaplasmosis).

### Serology

*B. burgdorferi* (LYM)  
Rickettsia (RIC)

### PCR

*Pan-Ehrlichia spp.* (ECP)\*  
*A. phagocytophilum* (APH)\*

### Accepted Specimens

1.0 ml of serum **AND** 5.0 ml of whole blood collected in EDTA. For pediatric specimens, collect 1.0 ml of serum and 1.0 ml whole blood in EDTA. Maintain at 4°C until delivered.

### Specimens Receipt

Specimens accepted Monday through Friday.

### Assay Schedule

Each assay is set up Monday through Friday, with final results usually available by 2:00 pm on the day of receipt.

### Normal Range

Lyme: IgG/IgM-Negative  
Rickettsia: IgG < 1:64  
Rickettsia: IgM < 1:64  
*Pan-Ehrlichia spp.*: PCR-Not detected  
*A. phagocytophilum*: PCR-Not detected

### CPT Codes

**LYM:** 86618  
**RIC:** 86757  
**ECP:** 87798  
**APH:** 87798

*\*This test was developed, and its performance characteristics determined by the Infectious Diseases Laboratory using Analyte Specific Reagents. It has not been cleared or approved by the FDA. This test is used for clinical purposes and should not be regarded as investigational or for research. This laboratory is regulated under the CLIA Amendments of 1988, 42 U.S.C. §263a as qualified to perform high-complexity clinical testing of this nature.*